Skip to Content
Merck

CIC protein instability contributes to tumorigenesis in glioblastoma.

Nature communications (2019-02-10)
Severa Bunda, Pardeep Heir, Julie Metcalf, Annie Si Cong Li, Sameer Agnihotri, Stefan Pusch, Mamatjan Yasin, Mira Li, Kelly Burrell, Sheila Mansouri, Olivia Singh, Mark Wilson, Amir Alamsahebpour, Romina Nejad, Bethany Choi, David Kim, Andreas von Deimling, Gelareh Zadeh, Kenneth Aldape
ABSTRACT

Capicua (CIC) is a transcriptional repressor that counteracts activation of genes downstream of receptor tyrosine kinase (RTK)/Ras/ERK signaling. It is well-established that tumorigenesis, especially in glioblastoma (GBM), is attributed to hyperactive RTK/Ras/ERK signaling. While CIC is mutated in other tumors, here we show that CIC has a tumor suppressive function in GBM through an alternative mechanism. We find that CIC protein levels are negligible in GBM due to continuous proteasome-mediated degradation, which is mediated by the E3 ligase PJA1 and show that this occurs through binding of CIC to its DNA target and phosphorylation on residue S173. PJA1 knockdown increased CIC stability and extended survival using in-vivo models of GBM. Deletion of the ERK binding site resulted in stabilization of CIC and increased therapeutic efficacy of ERK inhibition in GBM models. Our results provide a rationale to target CIC degradation in Ras/ERK-driven tumors, including GBM, to increase efficacy of ERK inhibitors.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Methyl cellulose, 27.5-31.5% (Methoxyl content), viscosity: 400 cP
Sigma-Aldrich
Monoclonal ANTI-FLAG® M2 antibody produced in mouse, 1 mg/mL, clone M2, affinity isolated antibody, buffered aqueous solution (50% glycerol, 10 mM sodium phosphate, and 150 mM NaCl, pH 7.4)
Sigma-Aldrich
TWEEN® 80, viscous liquid
Sigma-Aldrich
Anti-MAP Kinase (ERK-1, ERK-2) antibody produced in rabbit, whole antiserum
Sigma-Aldrich
Monoclonal Anti-β-Actin antibody produced in mouse, clone AC-74, ascites fluid